Business
Exicure Presents Positive Biomarker Results from Clinical Trial of XCUR17
-- XCUR17 clinical results announced in presentation at the 15th Annual Meeting of the Oligonucleotide Therapeutics Society in Munich -- -- Clinical results
About this update from Exicure, Inc.
[{"type":"text","content":"\n-- XCUR17 clinical results announced in presentation at the 15th Annual Meeting of the Oligonucleotide Therapeutics Society in Munich --\n\n\n-- Clinical results presented show decrease in the levels of psoriasis and inflammation markers --\n\n CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nExicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced that its chief executive officer, Dr. David Giljohann, presented clinical data from the company’s drug candidate XCUR17 in psoriasis today during the Oligonucleotides Clinical Studies session at the 15th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Munich.\n\n\nThe presentation titled, “Clinical Results from XCUR17, a Topically Applied Antisense Spherical Nucleic Acid in Patients with Psoriasis,” highlighted work by Dr. James Krueger at The Rockefeller University, in collaboration with Exicure, to examine the effects of XCUR17 in Phase 1 patient samples. In that study, all patients received daily applications of three strengths of XCUR17 gel and vehicle gel to different areas of psoriatic skin for 25 days. Biopsies were collected from the application areas after the 25 day treatment period as well as from lesional and nonlesional skin at baseline.\n\n\nClinical findings, correlated with psoriasis-related markers and histological changes from biopsies provided by the patients (n = 21), showed that XCUR17 treatment:\n\n\n\nResulted in a decrease in the levels of psoriasis and inflammation markers downstream of XCUR17's target, IL-17RA\n\n\nProduced a statistically significant reduction in keratin 16 expression, a key marker of psoriasis (p=0.002)\n\n\nResulted in reductions in the major inflammatory markers beta defensin 4A, interleukin 19, and interleukin 36A versus psoriatic skin at baseline\n\n\nRevealed clinical improvements that matched reductions in keratin 16 protein and epidermal thickness\n\n\n\nToday’s clinical update follows a December 17, 2018 company announcement of top-line results from a Phase 1 trial evaluating XCUR17 in patients with mild-to-moderate chronic plaque psoriasis. In that trial, the highest strength XCUR17 gel showed a statistically significant improvement in psoriasis symptoms. Such findings from the Phase 1 trial suggest that SNA-based drugs, ...